Active Ingredient: Prazepam
Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, between 10 milligrams prazepam and 60 milligrams prazepam, divided daily, 1 to 2 doses in total, over the duration of 4 weeks.
The usual dose is 30 mg daily in single or divided doses. The dose should be adjusted within the range 10 mg to 60 mg daily in accordance with response of the patient.
The lowest dose which can control symptoms should be used. It should not be usually continued beyond four weeks.
Treatment should be as short as possible. The patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free. The overall duration of treatment generally should not be more than 4-6 weeks, including a tapering off process.
In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient’s status with special expertise.
For:
Oral, between 10 milligrams prazepam and 15 milligrams prazepam, divided daily, over the duration of 4 weeks.
In elderly patients the initial dose should be small, and increments should be made gradually, in accordance with the response of the patient, to preclude ataxia or excessive sedation. Half the normal adult dose is generally sufficient for a therapeutic response in the elderly or debilitated.
The patient should be checked regularly at the start of the treatment and then regularly thereafter, in order to decrease if necessary, the dose or frequency of administration to prevent overdose due to accumulation.
Treatment should be as short as possible. The patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free. The overall duration of treatment generally should not be more than 4-6 weeks, including a tapering off process.
In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient’s status with special expertise.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
